应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。
关闭
EWTX Edgewise Therapeutics, Inc.
休市中 02-06 16:00:00 EST
29.10
+1.91
+7.02%
盘后
29.10
+0.00
0.00%
18:42 EST
最高
29.51
最低
27.78
成交量
91.76万
今开
28.06
昨收
27.19
日振幅
6.36%
总市值
30.81亿
流通市值
17.62亿
总股本
1.06亿
成交额
2,657万
换手率
1.52%
流通股本
6,053万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
Edgewise Therapeutics计划于2026年下半年启动EDG-7500针对梗阻性和非梗阻性HCM患者的III期临床试验
美股速递 · 01-13
Edgewise Therapeutics计划于2026年下半年启动EDG-7500针对梗阻性和非梗阻性HCM患者的III期临床试验
Edgewise Therapeutics公司预计2026年上半年公布Edg-7500治疗肥厚型心肌病的二期试验结果
美股速递 · 01-13
Edgewise Therapeutics公司预计2026年上半年公布Edg-7500治疗肥厚型心肌病的二期试验结果
Edgewise Therapeutics, Inc.：预计2026年第二季度公布完整12周Part D数据，计划在2026年第四季度启动三期试验
美股速递 · 2025-12-24
Edgewise Therapeutics, Inc.：预计2026年第二季度公布完整12周Part D数据，计划在2026年第四季度启动三期试验
Edgewise Therapeutics, Inc.盘中异动 早盘大幅下挫5.05%
市场透视 · 2025-12-03
Edgewise Therapeutics, Inc.盘中异动 早盘大幅下挫5.05%
Edgewise Therapeutics任命商业生物科技高管Christopher Martin为董事会成员
美股速递 · 2025-11-20
Edgewise Therapeutics任命商业生物科技高管Christopher Martin为董事会成员
Edgewise Therapeutics第三季度运营费用为4685.8万美元
投资观察 · 2025-11-20
Edgewise Therapeutics第三季度运营费用为4685.8万美元
异动解读 | Edgewise Therapeutics盘中大涨5.42%，新任CFO任命提振投资者信心
异动解读 · 2025-11-10
异动解读 | Edgewise Therapeutics盘中大涨5.42%，新任CFO任命提振投资者信心
Edgewise Therapeutics 任命 Michael Nofi 为首席财务官，同时宣布现任首席财务官 R. Michael Carruthers 退休
美股速递 · 2025-11-10
Edgewise Therapeutics 任命 Michael Nofi 为首席财务官，同时宣布现任首席财务官 R. Michael Carruthers 退休
Edgewise Therapeutics, Inc.2024财年实现净利润-1.34亿美元，同比减少34.00%
市场透视 · 2025-03-09
Edgewise Therapeutics, Inc.2024财年实现净利润-1.34亿美元，同比减少34.00%
Edgewise Therapeutics(EWTX.US)获Scotiabank首次覆盖，给予跑赢大盘评级, 目标价50.00美元。
金融界 · 2025-03-08
Edgewise Therapeutics(EWTX.US)获Scotiabank首次覆盖，给予跑赢大盘评级, 目标价50.00美元。
Edgewise Therapeutics, Inc.盘中异动 快速上涨5.02%报28.05美元
市场透视 · 2025-03-07
Edgewise Therapeutics, Inc.盘中异动 快速上涨5.02%报28.05美元
Edgewise Therapeutics, Inc.盘中异动 快速跳水5.10%
市场透视 · 2025-02-25
Edgewise Therapeutics, Inc.盘中异动 快速跳水5.10%
Edgewise Therapeutics, Inc.盘中异动 股价大涨5.02%
市场透视 · 2025-02-22
Edgewise Therapeutics, Inc.盘中异动 股价大涨5.02%
Edgewise Therapeutics, Inc.盘中异动 股价大涨5.00%报26.66美元
市场透视 · 2025-02-19
Edgewise Therapeutics, Inc.盘中异动 股价大涨5.00%报26.66美元
Edgewise Therapeutics, Inc.盘中异动 大幅上涨5.83%
市场透视 · 2025-01-15
Edgewise Therapeutics, Inc.盘中异动 大幅上涨5.83%
【纳斯达克生物科技指数收跌1.84%】 成分股SpringWorks收跌12.33%，Inozyme跌12.21%，Onkure Therapeutics跌12.12%，Tevogen Bio Holdings跌10.14%表现倒数第四，C4则收涨7.00%涨幅第四大，Edgewise Therapeutics涨8.65%，Kymera涨9.03%，Oric Pharma也涨14.94%。
金融界 · 2025-01-15
【纳斯达克生物科技指数收跌1.84%】 成分股SpringWorks收跌12.33%，Inozyme跌12.21%，Onkure Therapeutics跌12.12%，Tevogen Bio Holdings跌10.14%表现倒数第四，C4则收涨7.00%涨幅第四大，Edgewise Therapeutics涨8.65%，Kymera涨9.03%，Oric Pharma也涨14.94%。
Edgewise Therapeutics, Inc.盘中异动 早盘急速下挫5.70%报26.14美元
市场透视 · 2025-01-06
Edgewise Therapeutics, Inc.盘中异动 早盘急速下挫5.70%报26.14美元
Edgewise Therapeutics, Inc.盘中异动 早盘股价大涨5.80%报33.94美元
市场透视 · 2024-11-27
Edgewise Therapeutics, Inc.盘中异动 早盘股价大涨5.80%报33.94美元
Edgewise Therapeutics, Inc.2024财年第三财季实现净利润-34.13百万美元，同比减少32.75%
市场透视 · 2024-11-16
Edgewise Therapeutics, Inc.2024财年第三财季实现净利润-34.13百万美元，同比减少32.75%
Edgewise Therapeutics, Inc.盘中异动 下午盘大幅下跌5.06%
市场透视 · 2024-11-14
Edgewise Therapeutics, Inc.盘中异动 下午盘大幅下跌5.06%
加载更多
公司概况
公司名称：
Edgewise Therapeutics, Inc.
所属市场：
NASDAQ
上市日期：
--
主营业务：
Edgewise Therapeutics, Inc.于2017年5月成立为特拉华州公司，总部位于科罗拉多州博尔德。 该公司是一家临床阶段的生物制药公司，致力于发现，开发和商业化针对严重，罕见的肌肉疾病的新疗法，这些药物对于医疗的需求尚未得到充分满足。公司的主要候选产品EDG-5506是一种口服小分子药物，旨在解决营养不良症的根本原因，包括杜氏肌营养不良（DMD）和贝克尔肌营养不良（BMD）。针对主要肌肉蛋白质和调节剂的精密药物候选产品的渠道，以解决广泛的遗传定义的肌肉疾病。
发行价格：
--
{"stockData":{"symbol":"EWTX","market":"US","secType":"STK","nameCN":"Edgewise Therapeutics, Inc.","latestPrice":29.1,"timestamp":1770411600000,"preClose":27.19,"halted":0,"volume":917552,"hourTrading":{"tag":"盘后","latestPrice":29.1,"preClose":29.1,"latestTime":"18:42 EST","volume":66273,"amount":1928528.1,"timestamp":1770421352574,"change":0,"changeRate":0,"amplitude":0.000687},"delay":0,"changeRate":0.07024641412283929,"floatShares":60533687,"shares":105868434,"eps":-1.570777,"marketStatus":"休市中","change":1.91,"latestTime":"02-06 16:00:00 EST","open":28.06,"high":29.51,"low":27.78,"amount":26574509.879904002,"amplitude":0.063626,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.570777,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1770627600000},"marketStatusCode":7,"adr":0,"listingDate":1616731200000,"exchange":"NASDAQ","adjPreClose":27.19,"preHourTrading":{"tag":"盘前","latestPrice":27.7,"preClose":27.19,"latestTime":"09:25 EST","volume":5,"amount":139.29,"timestamp":1770387902981,"change":0.51,"changeRate":0.018757,"amplitude":0.011033},"postHourTrading":{"tag":"盘后","latestPrice":29.1,"preClose":29.1,"latestTime":"18:42 EST","volume":66273,"amount":1928528.1,"timestamp":1770421352574,"change":0,"changeRate":0,"amplitude":0.000687},"volumeRatio":1.0839774079183706,"impliedVol":0.8203,"impliedVolPercentile":0.5179},"requestUrl":"/m/hq/s/EWTX","defaultTab":"news","newsList":[{"id":"1169638993","title":"Edgewise Therapeutics计划于2026年下半年启动EDG-7500针对梗阻性和非梗阻性HCM患者的III期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1169638993","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1169638993?lang=zh_cn&edition=full","pubTime":"2026-01-13 21:09","pubTimestamp":1768309759,"startTime":"0","endTime":"0","summary":"生物制药公司Edgewise Therapeutics近日宣布，其核心候选药物EDG-7500将于2026年下半年正式进入III期临床试验阶段。该试验将同时针对梗阻性及非梗阻性肥厚型心肌病患者群体展开，标志着公司在该疾病领域研发进程的重要突破。EDG-7500作为新一代心肌肌球蛋白抑制剂，此前已通过II期临床试验验证其安全性与初步疗效。这一研发进展不仅为HCM患者提供了新的治疗希望，更凸显了Edgewise Therapeutics在心血管疾病创新疗法领域的战略布局。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4007","EWTX"],"gpt_icon":0},{"id":"1118951729","title":"Edgewise Therapeutics公司预计2026年上半年公布Edg-7500治疗肥厚型心肌病的二期试验结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1118951729","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1118951729?lang=zh_cn&edition=full","pubTime":"2026-01-13 21:06","pubTimestamp":1768309589,"startTime":"0","endTime":"0","summary":"Edgewise Therapeutics公司宣布，其针对肥厚型心肌病（HCM）研发的创新药物Edg-7500，预计将在2026年上半年获得二期临床试验的关键数据。这一进展标志着公司在心血管疾病治疗领域的重要里程碑，有望为患者提供新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4539","EWTX"],"gpt_icon":0},{"id":"1128361463","title":"Edgewise Therapeutics, Inc.：预计2026年第二季度公布完整12周Part D数据，计划在2026年第四季度启动三期试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1128361463","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1128361463?lang=zh_cn&edition=full","pubTime":"2025-12-24 21:01","pubTimestamp":1766581271,"startTime":"0","endTime":"0","summary":"Edgewise Therapeutics, Inc.：预计2026年第二季度公布完整12周Part D数据，计划在2026年第四季度启动三期试验","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EWTX","BK4007","BK4539"],"gpt_icon":0},{"id":"2588848057","title":"Edgewise Therapeutics, Inc.盘中异动 早盘大幅下挫5.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=2588848057","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588848057?lang=zh_cn&edition=full","pubTime":"2025-12-03 00:17","pubTimestamp":1764692235,"startTime":"0","endTime":"0","summary":"北京时间2025年12月03日00时17分，Edgewise Therapeutics, Inc.股票出现波动，股价大幅下跌5.05%。Edgewise Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.03%。其相关个股中，Polyrizon Ltd.、Reviva Pharmaceuticals Holdings Inc C/Wts 25/12/2025、Ethzilla Corporation涨幅较大，Polyrizon Ltd.、Clearmind Medicine Inc.、Jasper Therapeutics, Inc.较为活跃，换手率分别为8412.37%、323.17%、185.84%，振幅较大的相关个股有Polyrizon Ltd.、Akari Therapeutics Plc、Sonnet Biotherapeutics Holdings, Inc.，振幅分别为79.43%、70.43%、50.65%。Edgewise Therapeutics, Inc.公司简介：Edgewise Therapeutics Inc是一家临床阶段的生物制药公司。该公司的候选产品是Sevasemten和EDG-7500。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025120300171595270e55&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025120300171595270e55&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4007","LENZ","BK4539","EWTX"],"gpt_icon":0},{"id":"1153959997","title":"Edgewise Therapeutics任命商业生物科技高管Christopher Martin为董事会成员","url":"https://stock-news.laohu8.com/highlight/detail?id=1153959997","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1153959997?lang=zh_cn&edition=full","pubTime":"2025-11-20 21:01","pubTimestamp":1763643706,"startTime":"0","endTime":"0","summary":"Edgewise Therapeutics任命商业生物科技高管Christopher Martin为董事会成员","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","EWTX","BK4539"],"gpt_icon":0},{"id":"1143839149","title":"Edgewise Therapeutics第三季度运营费用为4685.8万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1143839149","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1143839149?lang=zh_cn&edition=full","pubTime":"2025-11-20 00:57","pubTimestamp":1763571451,"startTime":"0","endTime":"0","summary":"11月6日讯 - Edgewise Therapeutics第三季度运营收入为-4685.8万美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","EWTX","BK4007"],"gpt_icon":0},{"id":"1122326450","title":"异动解读 | Edgewise Therapeutics盘中大涨5.42%，新任CFO任命提振投资者信心","url":"https://stock-news.laohu8.com/highlight/detail?id=1122326450","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1122326450?lang=zh_cn&edition=full","pubTime":"2025-11-10 23:26","pubTimestamp":1762788370,"startTime":"0","endTime":"0","summary":"周一盘中，Edgewise Therapeutics, Inc.股价大涨5.42%，引发市场关注。此次股价上涨与公司高层人事变动密切相关。Edgewise Therapeutics在当日早些时候宣布，任命Michael Nofi为新任首席财务官，同时现任CFO R. Michael Carruthers将退休。高管变动通常会对公司股价产生重大影响。投资者可能认为，新的领导层将为Edgewise Therapeutics带来新的发展机遇和更强的财务管理能力，从而提振了市场信心。然而，具体影响还有待进一步观察，投资者应密切关注公司未来的财务表现和战略调整。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["EWTX"],"gpt_icon":0},{"id":"1186696546","title":"Edgewise Therapeutics 任命 Michael Nofi 为首席财务官，同时宣布现任首席财务官 R. Michael Carruthers 退休","url":"https://stock-news.laohu8.com/highlight/detail?id=1186696546","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1186696546?lang=zh_cn&edition=full","pubTime":"2025-11-10 21:03","pubTimestamp":1762779798,"startTime":"0","endTime":"0","summary":"Edgewise Therapeutics 任命 Michael Nofi 为首席财务官，同时宣布现任首席财务官 R. Michael Carruthers 退休。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4539","EWTX"],"gpt_icon":0},{"id":"2518440030","title":"Edgewise Therapeutics, Inc.2024财年实现净利润-1.34亿美元，同比减少34.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518440030","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518440030?lang=zh_cn&edition=full","pubTime":"2025-03-09 00:01","pubTimestamp":1741449679,"startTime":"0","endTime":"0","summary":"3月9日，Edgewise Therapeutics, Inc.公布财报，公告显示公司2024财年净利润为-1.34亿美元，同比减少34.00%；其中营业收入为0.00美元，每股基本收益为-1.45美元。从资产负债表来看，Edgewise Therapeutics, Inc.总负债27.60百万美元，其中短期债务996000.00美元，资产负债比为0.18，流动比率为0.20。机构评级：截至2025年3月9日，当前有9家机构对Edgewise Therapeutics, Inc.目标价做出预测，其中目标均价为47.44美元，其中最低目标价为30.00美元，最高目标价为56.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250309000248abef98a0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250309000248abef98a0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["EWTX","LENZ"],"gpt_icon":0},{"id":"2517146142","title":"Edgewise Therapeutics(EWTX.US)获Scotiabank首次覆盖，给予跑赢大盘评级, 目标价50.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2517146142","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517146142?lang=zh_cn&edition=full","pubTime":"2025-03-08 06:25","pubTimestamp":1741386325,"startTime":"0","endTime":"0","summary":"Edgewise Therapeutics(EWTX.US)获Scotiabank首次覆盖，给予跑赢大盘评级, 目标价50.00美元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/08062548605321.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["EWTX","LENZ"],"gpt_icon":0},{"id":"2517193704","title":"Edgewise Therapeutics, Inc.盘中异动 快速上涨5.02%报28.05美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517193704","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517193704?lang=zh_cn&edition=full","pubTime":"2025-03-07 01:38","pubTimestamp":1741282683,"startTime":"0","endTime":"0","summary":"北京时间2025年03月07日01时38分，Edgewise Therapeutics, Inc.股票出现异动，股价大幅上涨5.02%。Edgewise Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.96%。其相关个股中，Plus Therapeutics, Inc.、Cardio Diagnostics Holdings Inc C/Wts To Pur Com、Aeon Biopharma, Inc.涨幅较大，Aeon Biopharma, Inc.、Plus Therapeutics, Inc.、Tonix Pharmaceuticals Holding Corp.较为活跃，换手率分别为3907.56%、3160.30%、227.79%，振幅较大的相关个股有Surrozen Inc C/Wts 01/08/2031 、Plus Therapeutics, Inc.、Tonix Pharmaceuticals Holding Corp.，振幅分别为125.28%、122.63%、71.44%。Edgewise Therapeutics, Inc.公司简介：Edgewise Therapeutics Inc是一家临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250307013803abeba4d6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250307013803abeba4d6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","BK4139","LENZ","BK4539","EWTX"],"gpt_icon":0},{"id":"2514870347","title":"Edgewise Therapeutics, Inc.盘中异动 快速跳水5.10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514870347","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514870347?lang=zh_cn&edition=full","pubTime":"2025-02-25 03:47","pubTimestamp":1740426440,"startTime":"0","endTime":"0","summary":"北京时间2025年02月25日03时47分，Edgewise Therapeutics, Inc.股票出现波动，股价快速下挫5.10%。截至发稿，该股报25.69美元/股，成交量40.8569万股，换手率0.43%，振幅5.62%。Edgewise Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.28%。其相关个股中，Nutriband Inc C/Wts 、Pepgen Inc.、Surrozen Inc C/Wts 01/08/2031 涨幅较大，Pepgen Inc.、Aditxt, Inc.、Allarity Therapeutics, Inc.较为活跃，换手率分别为324.52%、138.11%、40.17%，振幅较大的相关个股有Nutriband Inc C/Wts 、Pepgen Inc.、Surrozen Inc C/Wts 01/08/2031 ，振幅分别为176.22%、162.04%、81.92%。Edgewise Therapeutics, Inc.公司简介：Edgewise Therapeutics Inc是一家临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225034720a25256d4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225034720a25256d4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","LENZ","BK4539","EWTX","BK4139"],"gpt_icon":0},{"id":"2513973732","title":"Edgewise Therapeutics, Inc.盘中异动 股价大涨5.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2513973732","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2513973732?lang=zh_cn&edition=full","pubTime":"2025-02-22 00:06","pubTimestamp":1740154017,"startTime":"0","endTime":"0","summary":"北京时间2025年02月22日00时06分，Edgewise Therapeutics, Inc.股票出现异动，股价大幅上涨5.02%。截至发稿，该股报28.46美元/股，成交量30.7464万股，换手率0.32%，振幅5.20%。Edgewise Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.19%。其相关个股中，Osr Holdings, Inc.、Nkgen Biotech, Inc.、Osr Holdings Inc C/Wts 09/02/2028 涨幅较大，Nkgen Biotech, Inc.、Aditxt, Inc.、Osr Holdings, Inc.较为活跃，换手率分别为189.92%、135.39%、117.09%，振幅较大的相关个股有Osr Holdings, Inc.、Osr Holdings Inc C/Wts 09/02/2028 、Nkgen Biotech, Inc.，振幅分别为67.41%、57.50%、48.19%。Edgewise Therapeutics, Inc.公司简介：Edgewise Therapeutics Inc是一家临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250222000658988df2a1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250222000658988df2a1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4139","BK4539","BK4007","EWTX"],"gpt_icon":0},{"id":"2512193146","title":"Edgewise Therapeutics, Inc.盘中异动 股价大涨5.00%报26.66美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2512193146","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512193146?lang=zh_cn&edition=full","pubTime":"2025-02-19 02:06","pubTimestamp":1739901960,"startTime":"0","endTime":"0","summary":"北京时间2025年02月19日02时06分，Edgewise Therapeutics, Inc.股票出现波动，股价快速拉升5.00%。截至发稿，该股报26.66美元/股，成交量48.6326万股，换手率0.51%，振幅4.84%。Edgewise Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.66%。其相关个股中，Aditxt, Inc.、Solid Biosciences Inc.、Allogene Therapeutics, Inc.涨幅较大，Aditxt, Inc.、Moleculin Biotech, Inc.、Solid Biosciences Inc.较为活跃，换手率分别为640.36%、196.30%、163.51%，振幅较大的相关个股有Estrella Immunopharma Inc C/Wts 29/09/2028、Abvc Biopharma, Inc.、Allogene Therapeutics, Inc.，振幅分别为148.75%、92.00%、79.17%。Edgewise Therapeutics, Inc.公司简介：Edgewise Therapeutics Inc是一家临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502190206009627babe&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502190206009627babe&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["EWTX","BK4139","BK4007","BK4539","LENZ"],"gpt_icon":0},{"id":"2503408936","title":"Edgewise Therapeutics, Inc.盘中异动 大幅上涨5.83%","url":"https://stock-news.laohu8.com/highlight/detail?id=2503408936","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2503408936?lang=zh_cn&edition=full","pubTime":"2025-01-15 22:39","pubTimestamp":1736951949,"startTime":"0","endTime":"0","summary":"北京时间2025年01月15日22时39分，Edgewise Therapeutics, Inc.股票出现异动，股价急速上涨5.83%。Edgewise Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.67%。其相关个股中，Silexion Therapeutics Corp C/Wts Exp 15/08/2029 、Dermata Therapeutics Inc C/Wts 、Exicure, Inc.涨幅较大，Windtree Therapeutics, Inc.、Phio Pharmaceuticals Corp.、Oncolytics Biotech Inc.较为活跃，换手率分别为188.25%、79.81%、36.02%，振幅较大的相关个股有Eterna Therapeutics Inc.、180 Life Sciences Corp C/Wts 07/11/2025、Onconetix, Inc.，振幅分别为21.55%、18.45%、16.94%。Edgewise Therapeutics, Inc.公司简介：Edgewise Therapeutics Inc是一家临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025011522390998673d66&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025011522390998673d66&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["EWTX","LENZ","BK4139","BK4539","BK4007"],"gpt_icon":0},{"id":"2503368235","title":"【纳斯达克生物科技指数收跌1.84%】 成分股SpringWorks收跌12.33%，Inozyme跌12.21%，Onkure Therapeutics跌12.12%，Tevogen Bio Holdings跌10.14%表现倒数第四，C4则收涨7.00%涨幅第四大，Edgewise Therapeutics涨8.65%，Kymera涨9.03%，Oric Pharma也涨14.94%。","url":"https://stock-news.laohu8.com/highlight/detail?id=2503368235","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2503368235?lang=zh_cn&edition=full","pubTime":"2025-01-15 05:31","pubTimestamp":1736890304,"startTime":"0","endTime":"0","summary":"成分股SpringWorks收跌12.33%，Inozyme跌12.21%，Onkure Therapeutics跌12.12%，Tevogen Bio Holdings跌10.14%表现倒数第四，C4则收涨7.00%涨幅第四大，Edgewise Therapeutics涨8.65%，Kymera涨9.03%，Oric Pharma也涨14.94%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/01/15053147459494.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK4007","159632","EWTX","TQQQ","USJW.SI","03086","MNQmain","NVIW.SI","TVGN","NQmain","SQQQ","ARTL","QID","QLD","TSYW.SI",".IXIC","159837","BK4139","USAW.SI","PSQ","BK4539","NDX","LENZ","BK1147"],"gpt_icon":0},{"id":"2501253831","title":"Edgewise Therapeutics, Inc.盘中异动 早盘急速下挫5.70%报26.14美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2501253831","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2501253831?lang=zh_cn&edition=full","pubTime":"2025-01-06 22:44","pubTimestamp":1736174681,"startTime":"0","endTime":"0","summary":"北京时间2025年01月06日22时44分，Edgewise Therapeutics, Inc.股票出现异动，股价大幅下挫5.70%。截至发稿，该股报26.14美元/股，成交量2.6499万股，换手率0.03%，振幅2.96%。Edgewise Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.10%。其相关个股中，Scisparc Ltd.、Sab Biotherapeutics Inc C/Wts 22/10/2026 、Rocket Pharmaceuticals Inc C/Wts 02/09/2026 涨幅较大，Scisparc Ltd.、Cns Pharmaceuticals, Inc.、Cytomed Therapeutics Limited较为活跃，换手率分别为496.58%、243.25%、83.74%，振幅较大的相关个股有Klotho Neurosciences Inc C/Wts 21/06/2029 、Scisparc Ltd.、Cytomed Therapeutics Limited，振幅分别为39.34%、34.08%、33.91%。Edgewise Therapeutics, Inc.公司简介：Edgewise Therapeutics Inc是一家临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250106224441a2179963&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250106224441a2179963&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4539","BK4139","EWTX","BK4007"],"gpt_icon":0},{"id":"2486827077","title":"Edgewise Therapeutics, Inc.盘中异动 早盘股价大涨5.80%报33.94美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2486827077","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486827077?lang=zh_cn&edition=full","pubTime":"2024-11-27 22:31","pubTimestamp":1732717860,"startTime":"0","endTime":"0","summary":"北京时间2024年11月27日22时31分，Edgewise Therapeutics, Inc.股票出现异动，股价大幅拉升5.80%。截至发稿，该股报33.94美元/股，成交量1447股，换手率0.00%，振幅0.00%。Edgewise Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.00%。其相关个股中，Celularity Inc C/Wts 16/07/2026 、Cyclerion Therapeutics, Inc.、Tuhura Biosciences, Inc.涨幅较大，Cyclerion Therapeutics, Inc.、Outlook Therapeutics, Inc.、Molecular Templates, Inc.较为活跃，换手率分别为784.53%、23.12%、6.72%，振幅较大的相关个股有Cyclerion Therapeutics, Inc.、Elevai Labs, Inc.、Oragenics Inc.，振幅分别为13.97%、8.20%、6.38%。Edgewise Therapeutics, Inc.公司简介：Edgewise Therapeutics Inc是一家临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241127223100971a8dab&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241127223100971a8dab&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4539","BK4139","BK4007","EWTX","LENZ"],"gpt_icon":0},{"id":"2483218306","title":"Edgewise Therapeutics, Inc.2024财年第三财季实现净利润-34.13百万美元，同比减少32.75%","url":"https://stock-news.laohu8.com/highlight/detail?id=2483218306","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483218306?lang=zh_cn&edition=full","pubTime":"2024-11-16 00:00","pubTimestamp":1731686435,"startTime":"0","endTime":"0","summary":"11月16日，Edgewise Therapeutics, Inc.公布财报，公告显示公司2024财年第三财季净利润为-34.13百万美元，同比减少32.75%；其中营业收入为0.00美元，每股基本收益为-0.36美元。从资产负债表来看，Edgewise Therapeutics, Inc.总负债22.41百万美元，其中短期债务992000.00美元，资产负债比为0.23，流动比率为0.27。机构评级：截至2024年11月16日，当前有6家机构对Edgewise Therapeutics, Inc.目标价做出预测，其中目标均价为43.17美元，其中最低目标价为33.00美元，最高目标价为51.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241116000316a23b89cf&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241116000316a23b89cf&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","EWTX"],"gpt_icon":0},{"id":"2483513358","title":"Edgewise Therapeutics, Inc.盘中异动 下午盘大幅下跌5.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=2483513358","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483513358?lang=zh_cn&edition=full","pubTime":"2024-11-14 03:38","pubTimestamp":1731526720,"startTime":"0","endTime":"0","summary":"北京时间2024年11月14日03时38分，Edgewise Therapeutics, Inc.股票出现异动，股价快速下跌5.06%。截至发稿，该股报33.42美元/股，成交量32.2608万股，换手率0.34%，振幅6.39%。Edgewise Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.42%。其相关个股中，Nkgen Biotech Inc C/Wts 31/05/2028、Pulmatrix, Inc.、Calidi Biotherapeutics, Inc.涨幅较大，Elevai Labs, Inc.、Cyclacel Pharmaceuticals, Inc.、Calidi Biotherapeutics, Inc.较为活跃，换手率分别为619.13%、553.18%、161.95%，振幅较大的相关个股有Psyence Biomedical Ltd C/Wts 25/01/2029、Pulmatrix, Inc.、Celularity Inc C/Wts 16/07/2026 ，振幅分别为139.00%、86.83%、73.71%。Edgewise Therapeutics, Inc.公司简介：Edgewise Therapeutics Inc是一家临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241114033841a234ea0f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241114033841a234ea0f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4539","BK4139","EWTX","BK4007"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.edgewisetx.com","stockEarnings":[{"period":"1week","weight":0.0337},{"period":"1month","weight":0.1796},{"period":"3month","weight":0.6958},{"period":"6month","weight":1.295},{"period":"1year","weight":0.0143},{"period":"ytd","weight":0.1727}],"compareEarnings":[{"period":"1week","weight":-0.002},{"period":"1month","weight":0.0015},{"period":"3month","weight":0.0293},{"period":"6month","weight":0.0839},{"period":"1year","weight":0.139},{"period":"ytd","weight":0.0128}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Edgewise Therapeutics, Inc.于2017年5月成立为特拉华州公司，总部位于科罗拉多州博尔德。 该公司是一家临床阶段的生物制药公司，致力于发现，开发和商业化针对严重，罕见的肌肉疾病的新疗法，这些药物对于医疗的需求尚未得到充分满足。公司的主要候选产品EDG-5506是一种口服小分子药物，旨在解决营养不良症的根本原因，包括杜氏肌营养不良（DMD）和贝克尔肌营养不良（BMD）。针对主要肌肉蛋白质和调节剂的精密药物候选产品的渠道，以解决广泛的遗传定义的肌肉疾病。","yearOnYearQuotes":[{"month":1,"riseRate":0.8,"avgChangeRate":0.169596},{"month":2,"riseRate":0.2,"avgChangeRate":-0.062606},{"month":3,"riseRate":0.25,"avgChangeRate":-0.130852},{"month":4,"riseRate":0.2,"avgChangeRate":-0.050448},{"month":5,"riseRate":0.4,"avgChangeRate":-0.045849},{"month":6,"riseRate":0.4,"avgChangeRate":-0.050464},{"month":7,"riseRate":0.4,"avgChangeRate":0.001937},{"month":8,"riseRate":0.6,"avgChangeRate":-0.017665},{"month":9,"riseRate":0.6,"avgChangeRate":0.09895},{"month":10,"riseRate":0.6,"avgChangeRate":0.092429},{"month":11,"riseRate":0.4,"avgChangeRate":0.07088},{"month":12,"riseRate":0.2,"avgChangeRate":0.087485}],"exchange":"NASDAQ","name":"Edgewise Therapeutics, Inc.","nameEN":"Edgewise Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Edgewise Therapeutics, Inc.(EWTX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Edgewise Therapeutics, Inc.(EWTX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Edgewise Therapeutics, Inc.,EWTX,Edgewise Therapeutics, Inc.股票,Edgewise Therapeutics, Inc.股票老虎,Edgewise Therapeutics, Inc.股票老虎国际,Edgewise Therapeutics, Inc.行情,Edgewise Therapeutics, Inc.股票行情,Edgewise Therapeutics, Inc.股价,Edgewise Therapeutics, Inc.股市,Edgewise Therapeutics, Inc.股票价格,Edgewise Therapeutics, Inc.股票交易,Edgewise Therapeutics, Inc.股票购买,Edgewise Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Edgewise Therapeutics, Inc.(EWTX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Edgewise Therapeutics, Inc.(EWTX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}